Sigma Investment Counselors Inc. Purchases 389 Shares of Johnson & Johnson (NYSE:JNJ)

Sigma Investment Counselors Inc. raised its position in Johnson & Johnson (NYSE:JNJ) by 3.5% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 11,355 shares of the company’s stock after acquiring an additional 389 shares during the period. Sigma Investment Counselors Inc.’s holdings in Johnson & Johnson were worth $1,642,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of the company. AMF Tjanstepension AB increased its position in shares of Johnson & Johnson by 14.2% during the 3rd quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock worth $68,985,000 after purchasing an additional 52,997 shares during the last quarter. Wealth Group Ltd. acquired a new position in shares of Johnson & Johnson during the 3rd quarter worth approximately $213,000. Swedbank AB increased its position in shares of Johnson & Johnson by 5.3% during the 3rd quarter. Swedbank AB now owns 2,215,108 shares of the company’s stock worth $358,980,000 after purchasing an additional 111,570 shares during the last quarter. Smithbridge Asset Management Inc. DE increased its position in shares of Johnson & Johnson by 1.3% during the 3rd quarter. Smithbridge Asset Management Inc. DE now owns 40,715 shares of the company’s stock worth $6,598,000 after purchasing an additional 527 shares during the last quarter. Finally, Welch Group LLC increased its position in shares of Johnson & Johnson by 2.6% during the 3rd quarter. Welch Group LLC now owns 345,797 shares of the company’s stock worth $56,040,000 after purchasing an additional 8,701 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now directly owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $162.75 on Thursday. The stock has a fifty day moving average price of $150.08 and a 200-day moving average price of $155.97. The company has a market cap of $391.83 billion, a price-to-earnings ratio of 24.47, a PEG ratio of 2.56 and a beta of 0.52. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same period in the prior year, the company posted $2.29 EPS. The company’s revenue was up 5.3% compared to the same quarter last year. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.05%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Analyst Ratings Changes

Several research firms have weighed in on JNJ. Wolfe Research began coverage on Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 price target on the stock. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Raymond James decreased their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Barclays boosted their target price on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 28th. Finally, Wells Fargo & Company decreased their target price on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $170.67.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.